Alnylam Pharmaceuticals
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.About ALNY
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference.
ALNY Key Statistics
Stock Snapshot
With a market cap of 49.13B, Alnylam Pharmaceuticals(ALNY) trades at $370.84. The stock has a price-to-earnings ratio of 1656.78.
As of 2026-01-12, Alnylam Pharmaceuticals(ALNY) stock has fluctuated between $353.52 and $384.74. The current price stands at $370.84, placing the stock +4.9% above today's low and -3.6% off the high.
The Alnylam Pharmaceuticals(ALNY)'s current trading volume is 3.45M, compared to an average daily volume of 1M.
During the past year, Alnylam Pharmaceuticals(ALNY) stock moved between $205.87 at its lowest and $495.55 at its peak.
During the past year, Alnylam Pharmaceuticals(ALNY) stock moved between $205.87 at its lowest and $495.55 at its peak.
ALNY News
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) announced a new five-year roadmap, "Alnylam 2030," on Sunday, outlining the company’s focus on scaling its operations...
In trading on Tuesday, shares of Alnylam Pharmaceuticals Inc (Symbol: ALNY) crossed below their 200 day moving average of $256.13, changing hands as low as $255...
H.C. Wainwright analyst Patrick Trucchio notes Alnylam (ALNY) pre-announced Q4 and 2025 net product revenue results and gave a net product revenue guidance rang...
Analyst ratings
68%
of 31 ratingsMore ALNY News
In early trading on Monday, shares of DexCom topped the list of the day's best performing components of the Nasdaq 100 index, trading up 3.6%. Year to date, Dex...
(RTTNews) - Alnylam Pharmaceuticals, Inc. (ALNY) announced its new five-year strategy, "Alnylam 2030." The plan is designed to scale the company's operations by...
Alnylam Pharmaceuticals recently outlined plans, now in the past, to present a company overview, early 2025 revenue figures, and a new five-year strategy at the...
If you are wondering whether Alnylam Pharmaceuticals' current share price still makes sense after its strong run, this article will walk through what the number...
Analyst William Pickering from Bernstein maintained a Buy rating on Alnylam Pharma and decreased the price target to $491.00 from $525.00. Claim 70% Off TipRank...